Literature DB >> 33608145

A Danish nationwide study of risk factors associated with Type I and Type II endometrial cancer.

M T Faber1, C D Sperling2, A K K Bennetsen3, G L Aalborg4, S K Kjaer5.   

Abstract

OBJECTIVE: To examine risk factors for Type I and Type II endometrial cancer (EC) and to directly compare the influence of risk factors for Type II with Type I tumors. Furthermore, to examine whether risk factors for high-grade Type I and Type II tumors differed from low-grade Type I tumors.
METHODS: Women with EC diagnosed during 2000-2016 were identified in the Danish Cancer Registry. A case-control analysis was conducted with 1:15 random population controls matched on age and gender. Using conditional logistic regression, odds ratios and 95% confidence intervals on risk factors for Type I and II tumors were estimated. In case-case analyses, risk factors were evaluated in a direct comparison of cases grouped by tumor type and grade.
RESULTS: We identified 6958 women with Type I EC and 1206 women with Type II EC. In the case-control analysis, nulliparity and diabetes were associated with increased risk of both tumor types, whereas hormone replacement therapy only increased the risk of Type I EC. When directly comparing Type I and II tumors, the influence of BMI ≥ 30, current smoking, and parity ≥ 3 was strongest for Type I EC. The associations for the majority of risk factors were similar for Type II and high-grade Type I tumors compared with low-grade Type II tumors.
CONCLUSIONS: Risk factors for Type I and II tumors were overlapping suggesting that Type II tumors may be less estrogen-independent than previously anticipated. High-grade Type I tumors seemed to resemble Type II tumors more than low-grade Type I tumors.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID: 33608145     DOI: 10.1016/j.ygyno.2021.02.010

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  N6-Methyladenosine-Related Long Noncoding RNAs as Potential Prognosis Biomarkers for Endometrial Cancer.

Authors:  Rui Shi; Ziwei Wang; Jun Zhang; Zhicheng Yu; Lanfen An; Sitian Wei; Dilu Feng; Hongbo Wang
Journal:  Int J Gen Med       Date:  2021-11-16

2.  An Immune-Related Long Noncoding RNA Signature as a Prognostic Biomarker for Human Endometrial Cancer.

Authors:  Ziwei Wang; Yan Liu; Jun Zhang; Rong Zhao; Xing Zhou; Hongbo Wang
Journal:  J Oncol       Date:  2021-12-10       Impact factor: 4.375

3.  Oncological Safety of Diagnostic Hysteroscopy for Apparent Early-Stage Type II Endometrial Cancer: A Multicenter Retrospective Cohort Study.

Authors:  Hui Zhou; Kai-Fa Lai; Qian Xiang; Yu Xu; Qian-Wen Zhang; Cui Hu; Xi-Guang Mao; Cheng Chen; Wu Huang; Gong-Sheng Mi; Juan Shen; Yong Tian; Feng-Mei Ke
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

4.  Trends of cancer incidence in Qassim Region, a descriptive analysis of data from the Saudi Cancer registry 2002-2016.

Authors:  Bader Alshamsan
Journal:  Int J Health Sci (Qassim)       Date:  2022 Sep-Oct

5.  Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms.

Authors:  Clelia Madeddu; Elisabetta Sanna; Giulia Gramignano; Luciana Tanca; Maria Cristina Cherchi; Brunella Mola; Marco Petrillo; Antonio Macciò
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.